UCB to exit the primary care market in the U.S.
UCB accelerates transition to become patient-centric global biopharmaceutical leader with decision to exit the primary care market in the U.S.
03-Feb-2010 -
UCB announced that it plans to accelerate its U.S. transition to a purely specialty-focused biopharmaceutical company and will exit the primary care market in the U.S., effective 1 March 2010. This strategic decision impacts the reported 2009 net profit with one-time restructuring charges, while ...
allergy drugs
diseases
immunology
+5